Thur 1/21/2021 1:37:16 PM Sent:

Subject: RTR 21 January 2021; non-peer reviewed study UK-variant and Pfizer vaccine

Received: Thur 1/21/2021 1:37:17 PM


RoundTableReport 20210121.pdf

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.pdf

Dag,

Ter info onderstaande info uit het RTR van vandaag (20-01). Bijgevoegd het RTR en de genoemde studie:

A non peer-reviewed study published by Pfizer/BioNTech provides further evidence of the preserved neutralisation of pseudoviruses bearing the B.1.1.7 spike by BNT162b2- immune sera, which makes it very unlikely that the SARS-CoV-2 202012/1 lineage B.1.1.7 (variant detected in the UK), can escape BNT162b2- mediated protection. The results in this article are supportive of vaccination using the currently authorised mRNA vaccines in line with national recommendations even if the new variant B.1.1.7 is circulating in the country.



Dear colleague,

We are pleased to share with you the ECDC Round Table Report. This report summarizes the daily roundtable discussion and provides update on threats detected and monitored by Epidemic Intelligence. This report contains information that might be sensitive or under verification. Its distribution is restricted to intended users only.

For further distribution, translation or copy of contents please contact 5.1.2h @ecdc.europa.eu.

Best regards,

On behalf of ECDC 24/7 duty team



European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 5.1.2e / Fax +46

www.ecdc.europa.eu



	e 1			* T	
Con	110	entia	11V	No	tice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.